TY - JOUR T1 - Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 338 LP - 341 DO - 10.2967/jnumed.120.247924 VL - 62 IS - 3 AU - Regine Kluge AU - Tim Wittig AU - Thomas W. Georgi AU - Lars Kurch AU - Osama Sabri AU - W. Hamish Wallace AU - Tomasz Klekawka AU - Ana Fernández-Teijeiro AU - Francesco Ceppi AU - Jonas Karlén AU - Jane Pears AU - Michaela Cepelová AU - Alexander Fosså AU - Auke Beishuizen AU - Lisa Lyngsie Hjalgrim AU - Dieter Körholz AU - Christine Mauz-Körholz AU - Dirk Hasenclever Y1 - 2021/03/01 UR - http://jnm.snmjournals.org/content/62/3/338.abstract N2 - In first-line treatment of Hodgkin lymphoma (HL), Deauville scores 1–3 define complete metabolic remission. Interim 18F-FDG PET is also used for relapse-treatment adaptation; however, PET response criteria are not validated for relapse treatment. Methods: We performed a pairwise comparative analysis of early response to first- and second-line treatments in 127 patients with classic HL who experienced relapse. The patients participated in the prospective, multicenter EuroNet-PHL-C1 study. Residual uptake was measured retrospectively using the qPET method, a validated semiautomatic quantitative extension of the Deauville score. Empiric cumulative distribution functions of the qPET values were used to systematically analyze the response to first- and second-line treatments. Results: Individual patients responded variably to first- and second-line treatments. However, the empiric cumulative distribution functions of the qPET values from all patients were nearly superimposable. Conclusion: The findings support that first- and second-line treatments in HL do not require different response criteria. ER -